IPP Bureau
President of India inaugurates KLE Cancer Hospital
By IPP Bureau - January 04, 2025
The President said that there is a need to spread more and more awareness regarding the causes, diagnosis and treatment of cancer
Veeda Group rebrands as Veeda Lifesciences
By IPP Bureau - January 03, 2025
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
Abbott India appoints Prithwish K Banerji as Commercial Director - Women’s Health, Metabolics and International Business
By IPP Bureau - January 03, 2025
Prithwish has close to 28 years of experience in a Commercial role
Alembic Pharmaceuticals appoints Prag Goel as VP – Sales and Marketing (Megacare, Enteron and Osteofit business divisions)
By IPP Bureau - January 02, 2025
He is an experienced professional in the pharmaceutical industry with about 30 years of progressive experience
2025 will witness India assuming critical role in Global Biotechnology revolution, says Science Minister Dr. Jitendra Singh
By IPP Bureau - January 02, 2025
India's bio economy has experienced remarkable growth, skyrocketing from $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
Innovent receives NMPA approval for Taletrectinib Adipate capsule from NMPA
By IPP Bureau - January 02, 2025
DOVBLERON marks the 13th addition to Innovent’s commercial portfolio
FDA grants orphan drug designation to MicuRx's MRX-5 for non-tuberculous mycobacteria infections
By IPP Bureau - January 02, 2025
MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria
Innovent inks agreement with Roche for Novel DLL3 ADC
By IPP Bureau - January 02, 2025
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
Amcor completes sale of BCNA joint venture interest for $122 million
By IPP Bureau - January 02, 2025
Fiscal 2024 total sales for the joint venture were approximately $190 million
Huadong Medicine and SynerK to jointly develop a novel siRNA drug SNK-2726
By IPP Bureau - January 02, 2025
SynerK owns intellectual property rights of SNK-2726, which is currently in the IND filing preparation stage
Akums commissions new manufacturing facility for Lyophilized and Sterile dosage
By IPP Bureau - January 02, 2025
The facility is equipped with state-of-the-art technology to produce high-quality lyophilized (freeze-dried) products
Venus Remedies secures GMP certification for antibiotic carbapenem facility in Moldova
By IPP Bureau - January 01, 2025
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
Anthem Biosciences files DRHP for Rs. 3,395 crore IPO
By IPP Bureau - January 01, 2025
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Sanofi acquires rights to develop and commercialize Aficamten in Greater China
By IPP Bureau - January 01, 2025
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
Merck inks agreement with Hansoh Pharma for investigational Oral GLP-1 receptor agonist
By IPP Bureau - January 01, 2025
Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535
